NSHL
MCID: HDG001
MIFTS: 30

Hodgkin's Lymphoma, Nodular Sclerosis (NSHL)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Hodgkin's Lymphoma, Nodular Sclerosis

MalaCards integrated aliases for Hodgkin's Lymphoma, Nodular Sclerosis:

Name: Hodgkin's Lymphoma, Nodular Sclerosis 12 15
Hodgkin's Disease, Nodular Sclerosis 12 73
Hodgkin's Disease, Nodular Sclerosis of Unspecified Site 12
Classic Hodgkin Lymphoma, Nodular Sclerosis Type 59
Classical Hodgkin Lymphoma, Nodular Sclerosis 12
Hodgkin Lymphoma, Nodular Sclerosis 12
Hodgkin's Disease Nodular Sclerosis 12
Nshl 12

Characteristics:

Orphanet epidemiological data:

59

Classifications:



External Ids:

Disease Ontology 12 DOID:8838
ICD10 33 C81.1
ICD9CM 35 201.5
NCIt 50 C3518
SNOMED-CT 68 52248008
Orphanet 59 ORPHA98843
UMLS via Orphanet 74 C0152268
ICD10 via Orphanet 34 C81.1
UMLS 73 C0152268

Summaries for Hodgkin's Lymphoma, Nodular Sclerosis

MalaCards based summary : Hodgkin's Lymphoma, Nodular Sclerosis, also known as hodgkin's disease, nodular sclerosis, is related to ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus and hypotrichosis-deafness syndrome, and has symptoms including fever and night sweats. An important gene associated with Hodgkin's Lymphoma, Nodular Sclerosis is KLHDC8B (Kelch Domain Containing 8B), and among its related pathways/superpathways are Myometrial Relaxation and Contraction Pathways and Gap junction trafficking. The drugs Cyclophosphamide and Vincristine have been mentioned in the context of this disorder. Affiliated tissues include skin, and related phenotypes are hearing/vestibular/ear and nervous system

Related Diseases for Hodgkin's Lymphoma, Nodular Sclerosis

Diseases related to Hodgkin's Lymphoma, Nodular Sclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Related Disease Score Top Affiliating Genes
1 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.3
2 hypotrichosis-deafness syndrome 10.1 GJB2 GJB3
3 deafness, autosomal recessive 93 10.1 GJB2 GJB3
4 deafness, autosomal recessive 28 10.1 GJB2 GJB3
5 mental retardation, enteropathy, deafness, peripheral neuropathy, ichthyosis, and keratoderma 10.1 GJB2 GJB3
6 deafness, autosomal recessive 26 10.1 GJB2 SLC26A4
7 deafness, autosomal recessive 3 10.1 GJB2 MYO15A
8 deafness, autosomal dominant 24 10.1 GJB2 GJB6
9 ear malformation 10.1 GJB2 SLC26A4
10 knuckle pads, leukonychia, and sensorineural deafness 10.1 GJB2 GJB6
11 deafness, autosomal recessive 2 10.1 GJB2 MYO15A
12 deafness, x-linked 2 10.1 GJB2 GJB6
13 lymphoma, hodgkin, classic 10.1
14 lymphoma 10.1
15 rosai-dorfman disease 10.1
16 dfnb1 10.1 GJB2 GJB6
17 vohwinkel syndrome 10.1 GJB2 GJB6
18 deafness, autosomal recessive 67 10.1 GJB2 GJB3
19 palmoplantar keratosis 10.0 GJB2 GJB3
20 deafness, autosomal dominant 2a 10.0 GJB2 GJB6
21 deafness, autosomal recessive 85 10.0 MYO15A SLC26A4
22 drug-induced hearing loss 10.0 GJB2 GJB3 SLC26A4
23 deafness, autosomal recessive 83 10.0 MYO15A SLC26A4
24 pendred syndrome 10.0 GJB2 SLC26A4
25 deafness, autosomal recessive 23 10.0 GJB2 GJB6 SLC26A4
26 kid syndrome 10.0 GJB2 GJB3 GJB6
27 pseudoainhum 10.0 GJB2 GJB3 GJB6
28 keratitis, hereditary 10.0 GJB2 GJB6
29 deafness, autosomal recessive 1a 10.0 GJB2 GJB3 GJB6
30 deafness, autosomal dominant 6 10.0 GJB2 SLC26A4 STRC
31 knuckle pads 10.0 GJB2 GJB3 GJB6
32 erythrokeratodermia variabilis et progressiva 1 10.0 GJB2 GJB3 GJB6
33 deafness, autosomal dominant 13 10.0 GJB2 SLC26A4 STRC
34 clouston syndrome 10.0 GJB2 GJB3 GJB6
35 congenital cytomegalovirus 9.9 GJB2 GJB6 MT-RNR1
36 autosomal recessive nonsyndromic deafness 3 9.9 GJB2 MYO15A SLC26A4
37 skin disease 9.9 GJB2 GJB3 GJB6
38 corneal disease 9.9 GJB2 GJB6
39 branchiootic syndrome 1 9.9 GJB2 SLC26A4 TMC1
40 deafness, autosomal recessive 7 9.8 GJB2 MT-RNR1 TMC1
41 vestibular disease 9.8 GJB2 GJB3 GJB6 SLC26A4
42 deafness, autosomal recessive 4, with enlarged vestibular aqueduct 9.8 GJB2 GJB3 GJB6 SLC26A4
43 autosomal dominant nonsyndromic deafness 9.8 GJB2 GJB3 TMC1
44 deafness, autosomal recessive 16 9.8 GJB2 GJB6 SLC26A4 STRC
45 deafness, autosomal dominant 36 9.7 GJB2 MT-RNR1 SLC26A4 TMC1
46 inner ear disease 9.7 GJB2 GJB3 GJB6 MT-RNR1 SLC26A4
47 autosomal recessive nonsyndromic deafness 9.6 GJB2 MYO15A SLC26A4 TMC1
48 non-syndromic genetic deafness 9.6 GJB2 MYO15A STRC TMC1
49 deafness, autosomal recessive 30 9.5 GJB2 MT-RNR1 MYO15A SLC26A4 TMC1
50 autosomal recessive non-syndromic sensorineural deafness type dfnb 9.1 GJB2 GJB3 GJB6 MYO15A SLC26A4 STRC

Graphical network of the top 20 diseases related to Hodgkin's Lymphoma, Nodular Sclerosis:



Diseases related to Hodgkin's Lymphoma, Nodular Sclerosis

Symptoms & Phenotypes for Hodgkin's Lymphoma, Nodular Sclerosis

UMLS symptoms related to Hodgkin's Lymphoma, Nodular Sclerosis:


fever, night sweats

MGI Mouse Phenotypes related to Hodgkin's Lymphoma, Nodular Sclerosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hearing/vestibular/ear MP:0005377 9.43 GJB2 GJB6 MYO15A SLC26A4 STRC TMC1
2 nervous system MP:0003631 9.1 GJB2 GJB6 MYO15A SLC26A4 STRC TMC1

Drugs & Therapeutics for Hodgkin's Lymphoma, Nodular Sclerosis

Drugs for Hodgkin's Lymphoma, Nodular Sclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 114)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 6055-19-2, 50-18-0 2907
2
Vincristine Approved, Investigational Phase 3,Phase 2 57-22-7, 2068-78-2 5978
3
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
5
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
6
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
7
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
8
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
9
Vinorelbine Approved, Investigational Phase 3,Phase 2 71486-22-1 60780 44424639
10
Cisplatin Approved Phase 3,Phase 2 15663-27-1 2767 441203 84093
11
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
12
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
13
Vinblastine Approved Phase 3,Phase 2 865-21-4 241903 13342
14
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1 51-75-2 4033
15
Dacarbazine Approved, Investigational Phase 3,Phase 2 4342-03-4 5351166
16
Bleomycin Approved, Investigational Phase 3,Phase 2 11056-06-7 5360373
17
Procarbazine Approved, Investigational Phase 3,Phase 2 671-16-9 4915
18
Cortisone acetate Approved, Investigational Phase 3 1950-04-4, 50-04-4 5745
19
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
20
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
21
Prednisolone phosphate Approved, Vet_approved Phase 3,Phase 2 302-25-0
22
Methylprednisolone hemisuccinate Approved Phase 3,Phase 2 2921-57-5
23
Doxil Approved June 1999 Phase 3,Phase 2 31703
24
Cortisone Experimental Phase 3 53-06-5 222786
25
Prednisolone hemisuccinate Experimental Phase 3,Phase 2 2920-86-7
26
Imidazole Experimental, Investigational Phase 3,Phase 2 288-32-4 795
27 Antineoplastic Agents, Hormonal Phase 3,Phase 2
28
Isophosphamide mustard Phase 3,Phase 2,Phase 1 0
29 Adjuvants, Immunologic Phase 3,Phase 2
30 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
31 Immunologic Factors Phase 3,Phase 2,Phase 1
32 Anti-Inflammatory Agents Phase 3,Phase 2
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
34 Antiemetics Phase 3,Phase 2
35 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
36 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
37 Alkylating Agents Phase 3,Phase 2,Phase 1
38 Peripheral Nervous System Agents Phase 3,Phase 2
39 Hormones Phase 3,Phase 2
40 Antiviral Agents Phase 3,Phase 2,Phase 1
41 Gastrointestinal Agents Phase 3,Phase 2
42 Antibiotics, Antitubercular Phase 3,Phase 2
43 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
44 BB 1101 Phase 3
45 Antimitotic Agents Phase 3,Phase 2
46 Etoposide phosphate Phase 3,Phase 2,Phase 1
47 Anti-Bacterial Agents Phase 3,Phase 2
48 glucocorticoids Phase 3,Phase 2
49 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
50 Hormone Antagonists Phase 3,Phase 2

Interventional clinical trials:

(show all 41)
# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma Unknown status NCT00302003 Phase 3 doxorubicin hydrochloride;vincristine sulfate;prednisone;cyclophosphamide;ifosfamide;vinorelbine tartrate;dexamethasone;etoposide phosphate;cisplatin;cytarabine
2 Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Hodgkin's Lymphoma Unknown status NCT00041210 Phase 3 ABVD regimen;Stanford V regimen;dacarbazine;doxorubicin hydrochloride;etoposide;mechlorethamine hydrochloride;prednisone;vinblastine sulfate;vincristine sulfate
3 Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma Completed NCT00433433 Phase 3 ABVD q4 weeks;BEACOPP escalated q3 weeks
4 Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease Completed NCT00025259 Phase 3 Cisplatin;Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Prednisone;Vincristine Sulfate Liposome
5 Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin's Disease Completed NCT00002561 Phase 3 dacarbazine;doxorubicin hydrochloride;vinblastine
6 Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma Completed NCT00433459 Phase 3 cyclophosphamide;dacarbazine;prednisolone;prednisone;procarbazine hydrochloride;vincristine sulfate
7 Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma Completed NCT00003389 Phase 3 Doxorubicin;Bleomycin;Vinblastine;Dacarbazine;Vincristine;Mechlorethamine;Etoposide;Prednisone;Cyclophosphamide
8 Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma Active, not recruiting NCT00049595 Phase 3 ABVD regimen;BEACOPP regimen;cyclophosphamide;dacarbazine;doxorubicin hydrochloride;etoposide;prednisone;procarbazine hydrochloride;vinblastine sulfate;vincristine sulfate
9 Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma Active, not recruiting NCT00678327 Phase 3 cyclophosphamide;dacarbazine;doxorubicin hydrochloride;etoposide;prednisolone;procarbazine hydrochloride;vinblastine sulfate;vincristine sulfate
10 Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma Unknown status NCT00002715 Phase 2 Stanford V regimen;doxorubicin hydrochloride;etoposide;mechlorethamine hydrochloride;prednisone;vinblastine;vincristine sulfate
11 Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma Completed NCT00082966 Phase 2 17-N-allylamino-17-demethoxygeldanamycin/bortezomib
12 Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed or Refractory Hodgkin's Lymphoma Completed NCT00255723 Phase 2 carboplatin;etoposide;ifosfamide
13 SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Completed NCT00337194 Phase 2 vinorelbine tartrate;pegylated liposomal doxorubicin hydrochloride;gemcitabine hydrochloride
14 Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy Completed NCT00381940 Phase 2 ifosfamide;bortezomib;vinorelbine tartrate
15 A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma Completed NCT01460940 Phase 2 panobinostat;lenalidomide
16 Gemcitabine and Vinorelbine in Treating Young Patients With Recurrent or Refractory Hodgkin's Lymphoma Completed NCT00070304 Phase 2 gemcitabine hydrochloride;vinorelbine tartrate
17 Combination Chemotherapy in Treating Children With Refractory or Relapsed Hodgkin's Lymphoma Completed NCT00006760 Phase 2 ifosfamide;vinorelbine tartrate
18 Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma Completed NCT00132028 Phase 2 vorinostat
19 Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma Completed NCT00369681 Phase 2 Bleomycin;Dacarbazine;Doxorubicin;Vinblastine
20 Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Completed NCT00002461 Phase 2 carmustine;cisplatin;cyclophosphamide;etoposide
21 Combination Chemotherapy in Treating Younger Patients With Hodgkin Lymphoma Completed NCT00666484 Phase 2 cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisolone;procarbazine hydrochloride;vincristine sulfate
22 Combination Chemotherapy in Treating Young Male Patients With Hodgkin's Lymphoma Completed NCT00398554 Phase 2 cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vinblastine sulfate;vincristine sulfate
23 Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease Completed NCT00004010 Phase 2 ABVD regimen;cyclophosphamide;dacarbazine;doxorubicin hydrochloride;etoposide;prednisone;procarbazine hydrochloride;vinblastine sulfate;vincristine sulfate
24 PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma Recruiting NCT03226249 Phase 2 Dacarbazine;Doxorubicin Hydrochloride;Vinblastine Sulfate
25 Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Recruiting NCT03077828 Phase 2 Carboplatin;Etoposide;Ifosfamide
26 Brentuximab Vedotin and Nivolumab in Treating Participants With Early Stage Classic Hodgkin Lymphoma Recruiting NCT03712202 Phase 2 Bleomycin;Brentuximab Vedotin;Dacarbazine;Doxorubicin;Vinblastine
27 Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma Active, not recruiting NCT01535924 Phase 1, Phase 2 gemcitabine hydrochloride;bendamustine hydrochloride
28 Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma Active, not recruiting NCT01476410 Phase 2 brentuximab vedotin;doxorubicin hydrochloride;vinblastine;dacarbazine
29 Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma Active, not recruiting NCT00574496 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;gemcitabine hydrochloride;ifosfamide;mechlorethamine hydrochloride;melphalan;methotrexate;mycophenolate mofetil;prednisone;procarbazine hydrochloride;vincristine sulfate;vinorelbine tartrate
30 Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma Active, not recruiting NCT01118026 Phase 2 ABVD;BEACOPP
31 S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma Active, not recruiting NCT00822120 Phase 2 ABVD regimen;BEACOPP regimen;cyclophosphamide;dacarbazine;doxorubicin hydrochloride;etoposide;prednisone;procarbazine hydrochloride;vinblastine sulfate;vincristine sulfate
32 Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease Terminated NCT00225173 Phase 2 Doxorubicin;Vinblastine;Cyclophosphamide;Etoposide;Vincristine;Bleomycin;Gemcitabine;Vinorelbine;Prednisone
33 Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma Terminated NCT00112723 Phase 1, Phase 2 alvocidib
34 Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma Terminated NCT01390584 Phase 2 ABVD Induction;Escalated BEACOPP;Standard BEACOPP
35 Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment Withdrawn NCT00881387 Phase 2 gemcitabine hydrochloride;vinorelbine ditartrate
36 Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma Completed NCT00439361 Phase 1 Bortezomib;Carboplatin;Etoposide;Ifosfamide;Mesna
37 CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma Recruiting NCT02168140 Phase 1 6,8-bis(benzylthio)octanoic acid;bendamustine hydrochloride
38 Risk Adapted Beacopp Regimen for Standard and High Risk Hodgkin Lymphoma Completed NCT00305149 Not Applicable
39 Protein Biomarker Levels in Tissue Samples From Young Patients With Low-risk Hodgkin Lymphoma Completed NCT01366157
40 Registry of BrentuximabVedotinin Patients With R/R Anaplastic Large Cell Lymphoma or Classical HL Recruiting NCT03766516
41 Multi-center Clinical Study on the Diagnosis and Treatment Management of Rare Neurological Disease in Children Not yet recruiting NCT03649919

Search NIH Clinical Center for Hodgkin's Lymphoma, Nodular Sclerosis

Genetic Tests for Hodgkin's Lymphoma, Nodular Sclerosis

Anatomical Context for Hodgkin's Lymphoma, Nodular Sclerosis

MalaCards organs/tissues related to Hodgkin's Lymphoma, Nodular Sclerosis:

41
Skin

Publications for Hodgkin's Lymphoma, Nodular Sclerosis

Articles related to Hodgkin's Lymphoma, Nodular Sclerosis:

# Title Authors Year
1
Subclassification of Hodgkin's disease, nodular sclerosis type. Prognostic value? ( 7654047 )
1995
2
Lack of prognostic value of histopathologic parameters in Hodgkin's disease, nodular sclerosis type. A study of 123 patients with limited stage disease who had undergone laparotomy and were treated with radiation therapy. ( 1497468 )
1992

Variations for Hodgkin's Lymphoma, Nodular Sclerosis

Expression for Hodgkin's Lymphoma, Nodular Sclerosis

Search GEO for disease gene expression data for Hodgkin's Lymphoma, Nodular Sclerosis.

Pathways for Hodgkin's Lymphoma, Nodular Sclerosis

Pathways related to Hodgkin's Lymphoma, Nodular Sclerosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.62 GJB2 GJB3 GJB6
2
Show member pathways
10.79 GJB2 GJB3 GJB6

GO Terms for Hodgkin's Lymphoma, Nodular Sclerosis

Cellular components related to Hodgkin's Lymphoma, Nodular Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 stereocilium GO:0032420 9.26 MYO15A STRC
2 stereocilium tip GO:0032426 9.16 STRC TMC1
3 gap junction GO:0005921 9.13 GJB2 GJB3 GJB6
4 connexin complex GO:0005922 8.8 GJB2 GJB3 GJB6

Biological processes related to Hodgkin's Lymphoma, Nodular Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 inner ear development GO:0048839 9.26 GJB2 GJB6
2 detection of mechanical stimulus involved in sensory perception of sound GO:0050910 9.16 STRC TMC1
3 cell communication GO:0007154 9.13 GJB2 GJB3 GJB6
4 sensory perception of sound GO:0007605 9.1 GJB2 GJB6 MYO15A SLC26A4 STRC TMC1

Molecular functions related to Hodgkin's Lymphoma, Nodular Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 gap junction channel activity GO:0005243 8.62 GJB2 GJB3

Sources for Hodgkin's Lymphoma, Nodular Sclerosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....